Astellas surges to a new all-time high as a higher earnings forecast for the current fiscal year and reports on a clinical trial of an iPS-based development drug act as catalysts

Astellas Pharma surged and set a new post-listing high. A breaking report said that the company’s upward revision to its current fiscal-year forecast and news reports on clinical trials for an IPS development product had attracted investor attention.

Read in fullFrom the source, not the headline

sources corroborateOutlets reporting the same event

companies linkedAcross 0 themes, second pass

The story

Astellas Pharma came under heavy buying, and its share price set a new post-listing high. The upward revision to the company’s current fiscal-year forecast has been cited as a factor driving market interest.

The news identified clinical trial reports concerning an IPS (iPS cell) development product as a catalyst, saying that this became a reason for investors to buy. The article did not provide specific figures or details of the clinical trials.

The share price of a related stock is shown as related-stock information. The share price of Astellas Pharma’s related stock was ¥2675.0 (as of 10:46), well above the previous day’s level.

At a glance

SecurityAstellas Pharma Inc.

TrendSurged and set a new high

ReasonRaised its current fiscal-year forecast; IPS clinical trial reports provided a catalyst

Share priceThe share price of the related stock was ¥2675.0 (as of 10:46)

Reference information. Every claim resolves to something the story actually named.

Where this came from

We read each source in full and checked they agree on the core claim.

1/ 1 agree

All of them report the same thing.

google.comNews

AgreesOpen

Read the original articleGo to the source page

Reference information generated from public sources. It does not solicit or advise on investments. Prices are 15-minute delayed.